NAS:ONCE (USA) Also trade in: Germany UK

Spark Therapeutics Inc

$ 109.69 0.85 (0.78%)
Volume: 156,299 Avg Vol (1m): 1,972,597
Market Cap $: 4.22 Bil Enterprise Value $: 3.85 Bil
P/E (TTM): 0.00 P/B: 9.21
Earnings Power Value -95.82
Net Current Asset Value 5.51
Tangible Book 11.87
Projected FCF 0
Median P/S Value 144.38
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 7/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 8.24
Cash-To-Debt ranked higher than
54.27% of 1078 companies
in the Biotechnology industry.
Industry Max: 20856.43, Med: 64.02, Min: 0.01
ONCE: 8.24
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 8.24, Med: 512.25, Max: 10000
Current: 8.24
8.24
10000
Equity-to-Asset 0.60
Equity-to-Asset ranked higher than
60.16% of 763 companies
in the Biotechnology industry.
Industry Max: 3.47, Med: 0.69, Min: -9.46
ONCE: 0.6
Ranked among companies with meaningful Equity-to-Asset only.
Equity-to-Asset range over the past 10 years
Min: 0.6, Med: 0.85, Max: 0.93
Current: 0.6
0.6
0.93
Debt-to-Equity 0.11
Debt-to-Equity ranked lower than
100.00% of 500 companies
in the Biotechnology industry.
Industry Max: 35.66, Med: 0.28, Min: 0.01
ONCE: 0.11
Ranked among companies with meaningful Debt-to-Equity only.
Debt-to-Equity range over the past 10 years
Min: 0, Med: 0.01, Max: 0.11
Current: 0.11
0
0.11
Debt-to-EBITDA -0.26
Debt-to-EBITDA ranked lower than
100.00% of 196 companies
in the Biotechnology industry.
Industry Max: 1208.58, Med: 2.04, Min: 0.01
ONCE: -0.26
Ranked among companies with meaningful Debt-to-EBITDA only.
Debt-to-EBITDA range over the past 10 years
Min: -0.27, Med: -0.01, Max: -0.01
Current: -0.26
-0.27
-0.01
Piotroski F-Score 2
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 7.35
DISTRESS
GREY
SAFE
Beneish M-Score 14.64
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC -5563.99%
WACC 14.49%

Profitability & Growth : 3/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % -288.70
Operating Margin ranked lower than
65.78% of 792 companies
in the Biotechnology industry.
Industry Max: 46829238.82, Med: -113.97, Min: -1969600
ONCE: -288.7
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: -3837.54, Med: -621.31, Max: -214.46
Current: -288.7
-3837.54
-214.46
Net Margin % -124.33
Net Margin ranked lower than
55.18% of 792 companies
in the Biotechnology industry.
Industry Max: 49899604.52, Med: -111.91, Min: -2150400
ONCE: -124.33
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: -3836.75, Med: -612.66, Max: -121.78
Current: -124.33
-3836.75
-121.78
ROE % -16.95
ROE ranked higher than
66.53% of 989 companies
in the Biotechnology industry.
Industry Max: 326.78, Med: -42.82, Min: -100794.12
ONCE: -16.95
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: -85.47, Med: -39.84, Max: -15.61
Current: -16.95
-85.47
-15.61
ROA % -11.31
ROA ranked higher than
66.05% of 1084 companies
in the Biotechnology industry.
Industry Max: 224.74, Med: -34.77, Min: -3751.92
ONCE: -11.31
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: -51.17, Med: -35.15, Max: -11.02
Current: -11.31
-51.17
-11.02
ROC (Joel Greenblatt) % -221.35
ROC (Joel Greenblatt) ranked higher than
52.70% of 1036 companies
in the Biotechnology industry.
Industry Max: 641137.84, Med: -521.46, Min: -3427023.81
ONCE: -221.35
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: -681.65, Med: -383.94, Max: -181.21
Current: -221.35
-681.65
-181.21
3-Year Total Revenue Growth Rate 43.20
3-Year Revenue Growth Rate ranked higher than
96.47% of 651 companies
in the Biotechnology industry.
Industry Max: 906.3, Med: 1.1, Min: -100
ONCE: 21.2
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
3-Year Revenue Growth Rate range over the past 10 years
Min: 0, Med: 21.2, Max: 132.2
Current: 21.2
0
132.2
3-Year Total EBITDA Growth Rate -60.00
3-Year EBITDA Growth Rate ranked lower than
93.64% of 802 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 4.6, Min: -2038.5
ONCE: -35.5
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
3-Year EBITDA Growth Rate range over the past 10 years
Min: 0, Med: -86.8, Max: -35.5
Current: -35.5
0
-35.5
3-Year EPS w/o NRI Growth Rate -0.20
3-Year EPS w/o NRI Growth Rate ranked lower than
73.66% of 763 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 5.7, Min: -2103.4
ONCE: -0.2
Ranked among companies with meaningful 3-Year EPS w/o NRI Growth Rate only.
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: 0, Med: -18, Max: -0.2
Current: -0.2
0
-0.2

» ONCE's 30-Y Financials

Financials (Next Earnings Date: 2019-08-07)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:ONCE

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 325414    SIC : 2836
Compare TSE:4974 NAS:GBT NAS:IMMU NAS:RARE NAS:CRSP XSWX:GALE SZSE:002821 XBRU:ARGX NAS:AKCA XKRX:006280 SZSE:300294 NYSE:EBS NAS:FOLD NAS:ANAB NAS:PBYI NYSE:XON NAS:ASND NAS:HALO ROCO:4147 NAS:DNLI
Traded in other countries 272.Germany 0L8L.UK
Address 3737 Market Street, Suite 1300, Philadelphia, PA, USA, 19104
Spark Therapeutics Inc is a biotechnology company with a focus on gene therapy and orphan disease treatment. The company has one business segment, Pharmaceuticals, which is principally engaged in utilizing gene therapy to develop products to aid patients suffering from debilitating diseases. Spark has a pipeline with products that target choroideremia, genetic blinding conditions or inherited retinal disease, and a product targeting hematologic disorders. The company earns the vast majority of its revenue in the United States.

Ratios

Current vs industry vs history
PB Ratio 9.21
PB Ratio ranked higher than
53.22% of 962 companies
in the Biotechnology industry.
Industry Max: 2236, Med: 4.1, Min: 0.05
ONCE: 9.21
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 2.28, Med: 5.22, Max: 11
Current: 9.21
2.28
11
PS Ratio 59.86
PS Ratio ranked lower than
73.00% of 726 companies
in the Biotechnology industry.
Industry Max: 113071.43, Med: 9999, Min: 0.01
ONCE: 59.86
Ranked among companies with meaningful PS Ratio only.
PS Ratio range over the past 10 years
Min: 21.66, Med: 78.73, Max: 475.1
Current: 59.86
21.66
475.1
EV-to-EBIT -19.14
EV-to-EBIT ranked lower than
100.00% of 261 companies
in the Biotechnology industry.
Industry Max: 4391.42, Med: 22.17, Min: 0.02
ONCE: -19.14
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: -38.6, Med: -11.1, Max: -4.6
Current: -19.14
-38.6
-4.6
EV-to-EBITDA -19.88
EV-to-EBITDA ranked lower than
100.00% of 281 companies
in the Biotechnology industry.
Industry Max: 28816.43, Med: 18.08, Min: 0.02
ONCE: -19.88
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: -39.5, Med: -11.4, Max: -4.7
Current: -19.88
-39.5
-4.7
EV-to-Revenue 55.14
EV-to-Revenue ranked lower than
63.94% of 771 companies
in the Biotechnology industry.
Industry Max: 118933, Med: 13.69, Min: 0.05
ONCE: 55.14
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: 14, Med: 68.45, Max: 375.9
Current: 55.14
14
375.9
Current Ratio 5.94
Current Ratio ranked higher than
89.76% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.46, Min: 0.01
ONCE: 5.94
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 3.26, Med: 11.04, Max: 21.13
Current: 5.94
3.26
21.13
Quick Ratio 5.59
Quick Ratio ranked higher than
89.48% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.18, Min: 0.01
ONCE: 5.59
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 3.26, Med: 10.88, Max: 21.13
Current: 5.59
3.26
21.13
Days Inventory 663.46
Days Inventory ranked lower than
78.17% of 481 companies
in the Biotechnology industry.
Industry Max: 908.49, Med: 125.55, Min: 0.02
ONCE: 663.46
Ranked among companies with meaningful Days Inventory only.
Days Inventory range over the past 10 years
Min: 591.12, Med: 591.12, Max: 663.46
Current: 663.46
591.12
663.46
Days Sales Outstanding 107.00
Days Sales Outstanding ranked lower than
100.00% of 668 companies
in the Biotechnology industry.
Industry Max: 1096.56, Med: 64.17, Min: 0.06
ONCE: 107
Ranked among companies with meaningful Days Sales Outstanding only.
Days Sales Outstanding range over the past 10 years
Min: 107, Med: 253.19, Max: 267.22
Current: 107
107
267.22
Days Payable 529.92
Days Payable ranked higher than
94.78% of 536 companies
in the Biotechnology industry.
Industry Max: 1651.36, Med: 63.91, Min: 0.12
ONCE: 529.92
Ranked among companies with meaningful Days Payable only.
Days Payable range over the past 10 years
Min: 529.92, Med: 898.87, Max: 898.87
Current: 529.92
529.92
898.87

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -11.30
3-Year Share Buyback Rate ranked lower than
60.44% of 857 companies
in the Biotechnology industry.
Industry Max: 43.5, Med: -13.4, Min: -1815.4
ONCE: -11.3
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -19.1, Med: -11.3, Max: 0
Current: -11.3
-19.1
0

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 9.25
Price-to-Tangible-Book ranked higher than
60.96% of 894 companies
in the Biotechnology industry.
Industry Max: 800, Med: 5.32, Min: 0.05
ONCE: 9.25
Ranked among companies with meaningful Price-to-Tangible-Book only.
Price-to-Tangible-Book range over the past 10 years
Min: 2.98, Med: 5.32, Max: 9.6
Current: 9.25
2.98
9.6
Price-to-Median-PS-Value 0.76
Price-to-Median-PS-Value ranked higher than
78.47% of 678 companies
in the Biotechnology industry.
Industry Max: 126.94, Med: 0.92, Min: 0.01
ONCE: 0.76
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Price-to-Median-PS-Value range over the past 10 years
Min: 0.29, Med: 0.94, Max: 6.35
Current: 0.76
0.29
6.35
Earnings Yield (Joel Greenblatt) % -5.24
Earnings Yield (Greenblatt) ranked lower than
61.70% of 1081 companies
in the Biotechnology industry.
Industry Max: 5000, Med: -7.73, Min: -10000
ONCE: -5.24
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: -21.6, Med: -9, Max: -2.6
Current: -5.24
-21.6
-2.6

More Statistics

Revenue (TTM) (Mil) $ 69.82
EPS (TTM) $ -2.37
Beta 2.03
Volatility % 146.15
52-Week Range $ 34.53 - 114.2
Shares Outstanding (Mil) 38.41

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 2
Positive ROA N
Positive CFROA N
Higher ROA yoy Y
CFROA > ROA N
Lower Leverage yoy N
Higher Current Ratio yoy N
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy Y